Related Experiment Video
Updated: Aug 9, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
Biomarkers in psychotropic drug development: integration of data across multiple domains
Peter R Bieck1, William Z Potter
1Eli Lilly & Company, Neuroscience Therapeutic Area, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. bieck@lilly.com
Abstract:
This review focuses on the current status of biomarkers and/or approaches critical to assessing novel neuroscience targets with an emphasis on new paradigms and challenges in this field of research. The importance of biomarker data integration for psychotropic drug development is illustrated with examples for clinically used medications and investigational drugs. The question remains how to verify access to the brain. Early imaging studies including micro-PET can help to overcome this. However, in case of delayed tracer development or because of no feasible application of brain imaging effects of the molecule, using CSF as a matrix could fill this gap. Proteomic research using CSF will hopefully have a major impact on the development of treatments for psychiatric disorders.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Measurement of Bioavailability: Pharmacodynamic Methods
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods
Pharmacogenomics: Identification of New Drug Targets
Drug Therapy
Antianxiety Medications

